Drug intelligence / Profile preview

Univ. of Kentucky CYP1B1 compound 15

Development stage: Unknown
Lead developer: University of Kentucky

Overview

Univ. of Kentucky CYP1B1 compound 15: sourced facts only. name: "From a small library, compound 15 emerged as the lead, with picomolar CYP1B1 inhibition, and over 19,000-fold selectivity against its relative, CYP1A1." [PMID:36520541]; target: "From a small library, compound 15 emerged as the lead, with picomolar CYP1B1 inhibition, and over 19,000-fold selectivity against its relative, CYP1A1." [PMID:36520541]; developer: "Department of Chemistry, University of Kentucky, 505 Rose Street, Lexington, Kentucky40506, United States." [PMID:36520541]

Targets

CYP1B1 (Cytochrome P450 1B1)

Beyond the preview

Go deeper on Univ. of Kentucky CYP1B1 compound 15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univ. of Kentucky CYP1B1 compound 15.